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Drug-eluting stents versus bare metal stents for saphenous vein graft lesions: meta-analysis of randomized trials
Background: Percutaneous coronary interventions in saphenous vein graft lesions are associated with less favorable outcomes. Drug-eluting stents have been shown superior to bare metal stents in many patients and lesion subsets. Evidence from studies evaluating drug-eluting stents in saphenous vein graft lesions has been conflicting.
Methods:
We performed e meta-analysis of randomized trials comparing drug-eluting stents (DES) with bare metal stents (BMS) in patients undergoing stent implantation in saphenous vein graft lesions. Four trials with a total population of 812 patients were identified: 416 were treated with DES and 396 were treated with BMS. Clinical follow-up varied from 12 to 36 months. Primary end point was need for repeat revascularization. Other endpoints were mortality, myocardial infarction and stent thrombosis. Results: Patients undergoing implantation of DES had lower odds of requiring repeat revascularization procedures (OR 0.51, 95% CI: 0.32 to 0.81, pϭ0.004). On the other hand, there were no differences between patients treated with DES vs. BMS regarding the odds of death (OR 0.1.44, 95% CI: 0.38 to 5.46), myocardial infarction (OR 0.81, 95% CI: 0.26 to 2.52) and stent thrombosis (OR 0.73, 95% CI: 0.11 to 4.83).
Conclusions:
In patients undergoing stenting in saphenous vein graft lesions, DES reduce the need for repeat revascularization procedures while maintaining a comparable safety profile with BMS.
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Implication of peri-procedural biomarker elevation after stent implantation: analysis from the pooled XIENCE V trials 
Background:
The clinical relevance of biomarker elevation after PCI with contemporary stents is controversial. We therefore examined the 2-year rates of mortality after stenting from a large pooled experience with the Xience V everolimus-eluting stent (EES) in randomized trials and registry studies. Methods: All EES studies were included from which biomarker data (either troponin or CKMB) were collected routinely within 48 hours post-PCI normalized to the local hospital reference. Two-year mortality was examined according to peak post-PCI biomarker. Results: From the SPIRIT III, SPIRIT IV, XIENCE V USA, XIENCE V India, SPIRIT V Registry and SPIRIT Women Registry (Nϭ14897), post-PCI CKMB and/or troponin data were available in 8,491 and 3,788 pts respectively. Any post-PCI CKMB or troponin elevation Ͼ the upper limits of normal (ULN) occurred in 24.2% and 42.7% of pts respectively. In the 2 cohorts mortality at 2 years occurred in 245 (2.9%) and 129 (3.4%) of pts respectively. There was no relationship between any level of CK-MB or troponin elevation and 2-year mortality (Table) . Among the CK-MB cohort, by protocol definition a periprocedural Q-wave MI infarction was diagnosed in 19 pts, whereas a non-Q-wave MI occurred in 209 pts with elevated CKMB level (Ͼ1x normal). Mortality at 2 years was markedly increased in pts with Q-wave compared to non-Q-wave MI (21.1% vs. 4.8% respectively, pϭ0.02).
Conclusions:
In this large experience with DES implantation, peri-procedural biomarker elevation was common after stent implantation but was not associated with 2-year mortality, unless a new Q-wave MI developed. Background: There is uncertainty about influence of periprocedural ischemia and myonecrosis on long-term results of coronary artery bifurcation stenting (PCI). The aim of the study is to explore the influence of end-procedural ischemia (detected with intracoronary electrocardiography (icECG)) and post-procedural myonecrosis (troponin and CK-MB elevation) on revascularization rates (TLR) and cumulative MACEs at 9-12 months after PCI. Methods: After placement of intracoronary guidewires in main branch (MB) and side branch (SB) an uninsulated proximal ends of wires were connected to unipolar V leads. Intracoronary unipolar ECGs (icECG) were recorded before, during and after stent placement and at the end of procedure. The maximal ST-segment elevation during intervention and 5 min after the procedure was recorded in SB and MB. The patient population consists from 86 patients with stable/unstable angina. Provisional T-stenting was a default strategy. Results: 67 patients were followed for more than 9 month. 72% were males, age 66Ϯ8, diabetics 34%; 43% had previous myocardial infarction, 41% previous PCI. 58% had multivessel disease. The main treated vessel was LAD (72%). True bifurcation lesions (Medina xx1) were 58%. On icECG the maximal ST-segment elevation was 12Ϯ9 mm in MB and 8Ϯ7 mm in SB (pϭ.044). At the end procedure 44 patients had residual ST-segment changes (66%): 7(13%) SB only, 11(21%) MB only, 16(27%) in both, 8(12%) ST depression in SB or MB, 1(1.5%) was with SB ST-depression and MB ST-elevation, 1(1.5%) with ST-depression in both branches. Changes on icECG have 78% sensitivity, 97% specificity for detection of post-procedural troponin elevation (32, 48%). At 10Ϯ4 months are presented in table. 
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